Joint work projects aim to achieve `triple benefits` in the form of benefits for patients, the NHS and the pharmaceutical operator(s) involved. The expected benefits must be clearly stated in advance. Both the NHS organisation and the participating company may consider quantifying the expected benefits as an anticipated return on investment (ROI) before embarking on a joint work project. Each party must make an essential and defined contribution to the project and the transfers of value from companies must be made public. The contribution of resources can be in different forms, including people, expertise, equipment, communication channels, information technology and finance. Download PDF “Joint Working – a toolbox for industry and the NHS” All joint work projects must be supported by a formal joint working agreement1, the summary of which must be made public before the start of the project. Agreements should be made at company/organisational level and not with individual healthcare professionals. Agreements must include an exit strategy, contingency arrangements, clear milestones and the obligation to measure, maintain and document results to facilitate replication and scale across the NHS. 1 www.pmcpa.org.uk/thecode/InteractiveCode2016/Pages/Clause20.aspx Other governance guidelines are also included in the ABPI Code of Practice and can be discussed interactively on the Prescription Medicines Code of Practice Authority (PMCPA) website 3. Other examples are available as executive summaries on the ABPI Disclosure UK2 website. You can also read case studies on joint work in Annex 1 of this document and on the websites of ABPI members. .